Bvf Inc Protagonist Therapeutics, Inc Transaction History

Bvf Inc

$3.15 Billion
Q3 2024

A detailed history of Bvf Inc transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Bvf Inc holds 1,850,167 shares of PTGX stock, worth $77.1 Million. This represents 2.64% of its overall portfolio holdings.

Number of Shares

1,850,167

Previous 3,319,290 44.26%

Holding current value

$77.1 Million

Previous $115 Million 27.71%

% of portfolio

2.64%

Previous 3.52%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$33.72 - $47.33 $49.5 Million - $69.5 Million	-1,469,123 Reduced 44.26%	1,850,167 $83.1 Million
Q2 2024 Aug 14, 2024	SELL	$24.66 - $34.8 $10.8 Million - $15.2 Million	-436,700 Reduced 11.63%	3,319,290 $115 Million
Q1 2024 May 15, 2024	SELL	$21.79 - $32.15 $43.3 Million - $63.9 Million	-1,988,858 Reduced 34.62%	3,755,990 $109 Million
Q3 2023 Nov 14, 2023	BUY	$16.68 - $23.66 $32.8 Million - $46.6 Million	1,968,948 Added 52.15%	5,744,848 $95.8 Million
Q1 2023 May 15, 2023	BUY	$10.78 - $25.38 $40.7 Million - $95.8 Million	3,775,900 New	3,775,900 $86.8 Million
Q2 2022 Aug 15, 2022	SELL	$7.06 - $25.52 $21.7 Million - $78.5 Million	-3,076,381 Reduced 73.54%	1,106,838 $8.76 Million
Q1 2022 May 16, 2022	BUY	$23.34 - $36.08 $12.4 Million - $19.2 Million	531,460 Added 14.55%	4,183,219 $99.1 Million
Q4 2021 Feb 14, 2022	SELL	$17.63 - $37.1 $4.41 Million - $9.28 Million	-250,000 Reduced 6.41%	3,651,759 $125 Million
Q3 2021 Nov 15, 2021	BUY	$12.95 - $49.69 $1.91 Million - $7.34 Million	147,664 Added 3.93%	3,901,759 $69.1 Million
Q2 2021 Aug 16, 2021	SELL	$25.57 - $44.88 $5.25 Million - $9.22 Million	-205,356 Reduced 5.19%	3,754,095 $168 Million
Q1 2021 May 17, 2021	SELL	$19.02 - $31.15 $5.97 Million - $9.79 Million	-314,137 Reduced 7.35%	3,959,451 $103 Million
Q4 2020 Feb 12, 2021	BUY	$18.49 - $25.13 $35.2 Million - $47.8 Million	1,901,300 Added 80.15%	4,273,588 $86.2 Million
Q3 2020 Nov 13, 2020	BUY	$15.19 - $22.4 $75,950 - $112,000	5,000 Added 0.21%	2,372,288 $46.4 Million
Q2 2020 Aug 14, 2020	BUY	$6.19 - $18.84 $10.4 Million - $31.6 Million	1,674,858 Added 241.88%	2,367,288 $41.8 Million
Q1 2020 May 15, 2020	BUY	$5.4 - $9.22 $52,920 - $90,356	9,800 Added 1.44%	692,430 $4.89 Million
Q3 2019 Nov 14, 2019	SELL	$9.41 - $16.56 $3.59 Million - $6.31 Million	-381,172 Reduced 35.83%	682,630 $8.2 Million
Q2 2019 Aug 14, 2019	SELL	$8.98 - $12.96 $533,887 - $770,510	-59,453 Reduced 5.29%	1,063,802 $12.9 Million
Q1 2019 May 15, 2019	SELL	$6.5 - $13.77 $3.36 Million - $7.11 Million	-516,203 Reduced 31.49%	1,123,255 $14.1 Million
Q4 2018 Feb 14, 2019	SELL	$6.3 - $10.44 $6.16 Million - $10.2 Million	-978,509 Reduced 37.38%	1,639,458 $11 Million
Q3 2018 Nov 14, 2018	BUY	$6.82 - $11.26 $8.18 Million - $13.5 Million	1,200,000 Added 84.63%	2,617,967 $26.9 Million
Q2 2018 Aug 14, 2018	BUY	$5.99 - $9.1 $6.06 Million - $9.21 Million	1,012,367 Added 249.6%	1,417,967 $9.53 Million
Q1 2018 May 07, 2018	BUY	$8.46 - $23.08 $943,146 - $2.57 Million	111,483 Added 37.9%	405,600 $3.48 Million
Q4 2017 Feb 14, 2018	BUY	$14.47 - $20.8 $4.26 Million - $6.12 Million	294,117	294,117 $6.12 Million

Others Institutions Holding PTGX

# of Institutions

247

Shares Held

56.4M

Call Options Held

76.3K

Put Options Held

114K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.04B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bvf Inc with notifications on news.

Account